摘要
由Syndecan-2基因(SDC2)编码的跨膜蛋白在肿瘤发展中扮演着复杂多变的角色,其在不同的肿瘤及不同情况下,作用可表现为促进肿瘤或者抑制肿瘤的作用,甚至在一定情况下兼具两面性。值得注意的是,基于SDC2甲基化的检测技术已成功应用于结直肠癌的无创筛查,并在临床实践中显示出高度的敏感性。这使得SDC2成为一个极具前景的新型生物标志物和潜在的治疗靶点,其转化医学价值日益凸显。文章系统梳理了SDC2基因在肿瘤中的这种双重功能及其临床应用前景,希望能为临床诊疗工作提供理论基础和实用参考。
The transmembrane protein encoded by the syndecan-2 gene(SDC2)plays a multifaceted and context-dependent role in tumor development.Its function can manifest as either promoting or inhibiting tumor progression,or even exhibiting dual characteristics under specific conditions.Notably,detection technology based on SDC2methylation has been successfully applied to the non-invasive screening of colorectal cancer and has demonstrated high sensitivity in clinical practice.This makes SDC2 a highly promising novel biomarker and a potential therapeutic target,with its translational medical value becoming increassingly prominent.This article comprehensively reviews and synthesizes this dual functionality of the SDC2 gene in tumors and its clinical application prospects,aiming to provide a theoretical foundation and practical reference for clinical diagnosis and treatment.
作者
田荣乐
崔菲菲
叶振邦
付永亮
郑闪
黄文亭
Tian Rongle;Cui Feifei;Ye Zhenbang;Fu Yongliang;Zheng shan;Huang Wenting(Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021;Faculty of Medicine,Shenzhen University,Shenzhen 518060;Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen Hospital,Shenzhen 518116)
出处
《中国肿瘤临床与康复》
2025年第12期745-755,共11页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
中国医学科学院肿瘤医院深圳医院院内科研课题(E010224012)。
